At Speratum Biopharma, we are leveraging the power of microRNAs to develop cutting-edge therapies aimed at transforming patient outcomes, particularly in oncology. MicroRNAs are small, naturally occurring, non-coding RNA molecules that serve as key regulators of gene expression by binding to messenger RNA (mRNA), thereby blocking protein translation or initiating mRNA degradation. This mechanism allows microRNAs to control multiple cellular processes, making them pivotal in maintaining cellular function and health.

Discovered in 1993 and conserved across almost all mammalian species, microRNAs have proven to be crucial in regulating biological processes, such as immune response, cell-cycle control, metabolism, stem cell differentiation, and human development. Their conservation across species underscores their fundamental role in biology. The recent 2024 Nobel Prize awarded to Victor Ambros and Gary Ruvkun highlights the groundbreaking nature of microRNA research, recognizing its significance in gene regulation.

With over 2,600 predicted mature human microRNAs, including around 600 well-validated targets, the therapeutic potential in addressing diseases driven by dysregulated microRNA activity is immense. Alterations in microRNA expression have been linked to cancer, fibrosis, and numerous other conditions, including CNS, metabolic, and inflammatory disorders.

At Speratum Biopharma, we are pioneering therapies that target these pathways using our proprietary Nano-In and NoPass platforms. Our work is focused on modulating microRNA activity to disrupt cancer progression, offering a novel approach to precision medicine. By targeting the root cause of disease at the molecular level, we aim to develop therapies that are not just innovative but also life-changing for patients facing complex conditions.